Propanc Biopharma prices $4M public offering, uplists to Nasdaq; appoints two independent directors

Propanc Biopharma, Inc.

Raised $4M gross ($3.34M net) via public offering of 1M shares at $4.00/sh; underwriters have 45-day option for 150K more.
Common stock began trading on Nasdaq Capital Market on Aug 15 under symbol PPCB, uplisted from OTC Pink.
Appointed Joseph Himy and Annie VanBroekhoven as independent directors on Aug 14; serving on audit, compensation, nominating committees.
Issued Representative's warrants to D. Boral Capital for 30,000 shares at $4.00, exercisable from Feb 2026 to Aug 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.